The efficacy of adjunctive <i>Garcinia mangostana</i> Linn. (mangosteen) pericarp extract for bipolar depression: 24-week randomised controlled trial.

ABSTRACT:

Background

Bipolar depression remains difficult to treat, and people often experience ongoing residual symptoms, decreased functioning and impaired quality of life. Adjunctive therapies targeting novel pathways can provide wider treatment options and improve clinical outcomes. Garcinia mangostana Linn. (mangosteen) pericarp has serotonogenic, antioxidant anti-inflammatory and neurogenic properties of relevance to the mechanisms of bipolar depression.

Aims

The current 28-week randomised, multisite, double-blind, placebo-controlled trial investigated mangosteen pericarp extract as an adjunct to treatment-as-usual for treatment of bipolar depression.

Method

This trial was prospectively registered on the Australia New Zealand Clinical Trials Registry (no. ACTRN1261

SUBMITTER: Dean OM 

PROVIDER: S-EPMC12628125 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature